Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + filgrastim
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Cyclophosphamide + filgrastim is a combination regimen used primarily in oncology to enable higher-dose or dose-intensified chemotherapy by mitigating the risk of severe neutropenia. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell death, and is widely used as an antineoplastic and immunosuppressive agent. Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from the bone marrow, reducing infection risk after myelosuppressive therapy. When administered together, filgrastim supports recovery from cyclophosphamide-induced neutropenia, allowing for higher or more frequent dosing of cytotoxic regimens in cancer treatment[1][2][3][5].
- Brand names
- CytoxanNeosarNeupogenZarxioNivestym
- Other names
- High-dose cyclophosphamide without stem cell rescueJohns Hopkins high-dose cyclophosphamide protocolHiDAC-G-CSF
02
Targets
DNACSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on cyclophosphamide + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + filgrastim.